"Metastatic gastric cancer patients" trang 1 - tải miễn phí từ tailieunhanh
Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
10    74    0
Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2- low advanced or metastatic gastric cancer: A multicenter real-world study

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2- low advanced or metastatic gastric cancer: A multicenter real-world study
8    1    1
A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer
10    61    1
Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients

Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients
8    2    1
A modified subclassification to evaluate the survival of patients with N3 gastric cancer: An international database study

A modified subclassification to evaluate the survival of patients with N3 gastric cancer: An international database study
10    29    1
Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy

Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy
11    83    0
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial
9    51    1
Early prediction of response to palliative chemotherapy in patients with stage-IV gastric and esophageal cancer

Early prediction of response to palliative chemotherapy in patients with stage-IV gastric and esophageal cancer
9    1    1
Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/ recurrent gastric cancer previously untreated with chemotherapy

Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/ recurrent gastric cancer previously untreated with chemotherapy
7    57    1
Meta-analysis shows that circulating tumor cells including circulating microRNAs are useful to predict the survival of patients with gastric cancer

Meta-analysis shows that circulating tumor cells including circulating microRNAs are useful to predict the survival of patients with gastric cancer
12    50    1
The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
7    37    1
Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: A multicenter retrospective study

Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: A multicenter retrospective study
12    34    3
Identifcation of metabolism-related genes for predicting peritoneal metastasis in patients with gastric cancer

Identifcation of metabolism-related genes for predicting peritoneal metastasis in patients with gastric cancer
11    13    1
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
8    49    1
Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma

Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma
13    61    3